Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review

Front Oncol. 2022 Nov 24:12:934249. doi: 10.3389/fonc.2022.934249. eCollection 2022.

Abstract

Most patients with advanced gastric cancer were treated with palliative therapy, which had a poor curative effect and a short survival time. In recent years, the clinical research of immune checkpoint inhibitors in advanced gastric cancer has made a breakthrough and has become an important treatment for advanced gastric cancer. The modes of immune checkpoint inhibitors in the treatment of advanced gastric cancer include single drug, combined chemotherapy, radiotherapy, and multiple immune drug combination therapy, among which combination therapy shows better clinical efficacy, and a large number of trials are currently exploring more effective combination therapy programs. In this paper, the new clinical research progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer is reviewed, with an emphasis on combination therapy.

Keywords: chemotherapy; gastric cancer; immune checkpoint inhibitors; radiotherapy; targeted therapy.

Publication types

  • Review